Skip to content

Zinc Deficiency in Dilated Cardiomyopathy

Oral Zinc Supplementation in Children With Dilated Cardiomyopathy : Aprospective Cohort Study in Assiut ,Egypt.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04860921
Enrollment
50
Registered
2021-04-27
Start date
2021-04-20
Completion date
2022-12-28
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zinc Deficiency

Keywords

Dilated cardiomopathy

Brief summary

The aim of this study is to detect effect of oral zinc supplementation in pediatric patients with dilated cardiomyopathy.

Detailed description

Cardiomyopathies are group of heart diseases that influence cardiac muscles directly and are not related to hypertension, congenital, valvular and pericardial diseases. The most common type of cardiomyopathy is dilate cardiomyopathy. Dilated cardiomyopathy usually manifests as chronic systolic heart failure leading to arrhythmias and sudden death. Trace elements are known to have a key role in myocardial metabolism. The human heart requires energy from micro and macro nutrients both to regenerate proteins and cells, and to support cyclic contractions. Heart failure is associated with neuro-hormonal activation leading to elevated levels of inflammatory markers and oxidative stress. Zinc is an essential micronutrient that impacts the cardiovascular system. There are multiple potential pathophysiologic causes for zinc deficiency in heart failure as result of impaired micronutrient consumption, hyper inflammatory state, diminished absorption and hyperzincuria from heart failure medications. Zinc deficiency may play a role as primary and possible reversible cause of dilated cardiomyopathy. Plasma zinc levels have been reported in multiple observational studies of patients with heart failure particularly in studies of idiopathic dilated cardiomyopathy, serum zinc levels have been found to be low. A small but growing body of evidence suggesting the role for oral zinc supplementation in the management of dilated cardiomyopathy however further evaluation of the impact on outcome is needed.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* children (1-18) year's age with impaired left ventricular systolic function due to dilated cardiomyopathy

Exclusion criteria

* patients with congenital heart diseases. * patients less than one year age.

Design outcomes

Primary

MeasureTime frameDescription
New york heart associaton functional classification for grading heart failure1.5 yearAll cases included the study will be carefully examined for sings of heart failure according to new york heart association classification for grading of heart failure

Secondary

MeasureTime frameDescription
Detailed echocardiographic examination1.5 yearDetailed echocardiography using Phillips Envisor C according to the guidelines of the American society of echocardiography(18)،focusing on follow up of left ventricle end diastolic dimension Z-score ,left ventricle fractional shortening and ejection fraction.

Contacts

Primary ContactSafaa Ahmed
Safaa.20124126@med.au.edu.eg01096449446
Backup ContactSafaa Sholkamy
Safaasholkamy1000@yahoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026